Chinese player HOMTOM appoints product head for India
New Delhi, July 11: China-based handset maker HOMTOM that came to India last month on Wednesday announced to appoint Nikhil Bhutani as India Director for its product and operations.
Prior to joining HOMTOM, Bhutani has worked as the Regional Head of Ziox Mobile.
"We emphasise upon bringing superior-quality devices, loaded with latest features, at affordable prices to the Indian market in line with the brand's vision of offering 'smarterphone's for a smarter India," Bhutani said in a statement.
Part of Shenzhen Zhouji Hengtong Technology Co Ltd and incepted in 2013, HOMTOM offers original design manufacturing (ODM) services to smartphone companies globally.
The company debuted in India with five mid-price smartphones starting at Rs 8,000 and has plans to manufacture handsets in India.
"We are elated to have Nikhil on board with HOMTOM. With our new office now operational in Noida, we are planning to launch 'smarterphones' in mid to high-end segments," said Gary Zhang, CEO, HOMTOM.
As an R&D company, HOMTOM claims to hold more than 100 patents globally.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Statewide ban on IV Ringer Lactate usage: Dinesh Gundu Rao
Bengaluru: In response to the deaths of postnatal women at Ballari District Hospital, the Karnataka government has temporarily suspended the use of IV Ringer Lactate solution across the state as a precautionary measure, Health Minister Dinesh Gundu Rao announced on Saturday.
Speaking to the media in Bengaluru, the minister explained that doubts about the quality of the IV solution had arisen, prompting the decision. He clarified that Ringer Lactate, along with glucose solutions, has been routinely used in hospitals for years. However, out of the 192 batches supplied by the Karnataka State Drugs Logistics and Warehousing Society, concerns were raised regarding two specific batches.
"In light of these concerns, we stopped the use of all 192 batches as a precaution. Following this, the supplying company obtained a High Court order for testing, and the Central Drugs Laboratory (CDL) conducted an analysis. The CDL report confirmed the usability of the solution, allowing the state to form a technical committee to review and permit the use of certain batches that met quality standards. Despite this, doubts have surfaced specifically at Ballari District Hospital," the minister stated.
To address these concerns, the batches supplied to Ballari Hospital have been sent for anaerobic testing to determine whether the IV solution contributed to the deaths. The test results are expected within a week, after which a final decision on the use of IV Ringer Lactate will be made.
"Until then, we have issued directives to hospitals statewide to suspend the use of IV Ringer Lactate. Every life is important to us, and precautionary measures are essential when suspicions arise," Gundu Rao emphasised.
